Those results suggested that the sub-cluster of colon cancer patients with lack of CDX2 expression not only could benefit from adjuvant chemotherapy, but also preferentially benefit from BRAF inhibitors or PI3K-mTOR inhibitors treatment. This evidence concerns the gene PIK3CA and colonic neoplasm.